Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses

• DOI: 10.1136/jitc-2024-009710
• Publication Date: 2024-10-02T12:35:20Z
• Authors: Yijun Dong; Zongliang Zhang; Siyuan Luan; Meijun Zheng; Zeng Wang; Yongdong Chen; Xiaoting Chen; Aiping Tong; Hui Yang
• Keywords: Immunogenic cell death; Antibody-drug conjugate

Antibody-drug conjugates (ADCs) offer a promising approach, combining monoclonal antibodies with chemotherapeutic drugs to target cancer cells effectively while minimizing toxicity.